Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition

Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition

Abstract Basal-like breast cancers (BLBC) are aggressive breast cancers that respond poorly to targeted therapies and chemotherapies. In order to define therapeutically targetable subsets of BLBC we examined two markers: cyclin E1 and BRCA1 loss. In high grade serous ovarian cancer (HGSOC) these mar...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Diar Aziz, Neil Portman, Kristine J. Fernandez, Christine Lee, Sarah Alexandrou, Alba Llop-Guevara, Zoe Phan, Aliza Yong, Ashleigh Wilkinson, C. Marcelo Sergio, Danielle Ferraro, Dariush Etemadmoghadam, David D. Bowtell, kConFab Investigators, Violeta Serra, Paul Waring, Elgene Lim, C. Elizabeth Caldon
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/6daf1a428240435b83fc21ea45524a31
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares